RP.V - RepliCel Life Sciences Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.36
-0.01 (-2.70%)
At close: 3:34PM EDT
Stock chart is not supported by your current browser
Previous Close0.37
Open0.37
Bid0.34 x 0
Ask0.38 x 0
Day's Range0.36 - 0.38
52 Week Range0.33 - 1.04
Volume54,689
Avg. Volume30,816
Market Cap7.774M
Beta-0.19
PE Ratio (TTM)N/A
EPS (TTM)-0.43
Earnings DateNov 27, 2015 - Nov 30, 2015
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
  • RepliCel CEO Provides 2018 Shareholder Update
    CNW Group3 months ago

    RepliCel CEO Provides 2018 Shareholder Update

    VANCOUVER, Jan. 25, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF - News) (TSXV:RP.V - News) (FRA:P6P2.F - News) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler. The Company had a very successful 2017, which has only paved the way for a successful year as we enter into 2018. Looking back over the past 24 months, 2016 was about restructuring and refinancing the Company,  2017 was about delivering promised clinical and injector milestones, and now 2018 is about expansion.

  • PR Newswire3 months ago

    RepliCel CEO Provides 2018 Shareholder Update

    VANCOUVER, Jan. 25, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler. The Company had a very successful 2017, which has only paved the way for a successful year as we enter into 2018. Looking back over the past 24 months, 2016 was about restructuring and refinancing the Company,  2017 was about delivering promised clinical and injector milestones, and now 2018 is about expansion.

  • PR Newswire3 months ago

    RepliCel Life Sciences Lands Commitment for Key Investment Partnership

    VANCOUVER and NINGBO, Zhejiang Province, China, Jan. 16, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has signed a Binding Term Sheet (the "Term Sheet") with YOFOTO (China) Health Industry Co. Ltd. ("YOFOTO") to form a strategic partnership (the "Transaction") in Greater China (Mainland China, Hong Kong, Macau, and Taiwan) (the "Territory").

  • RepliCel Life Sciences Lands Commitment for Key Investment Partnership
    CNW Group3 months ago

    RepliCel Life Sciences Lands Commitment for Key Investment Partnership

    VANCOUVER and NINGBO, Zhejiang Province, China, Jan. 16, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF - News) (TSXV:RP.V - News) (FRA:P6P2.F - News) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has signed a Binding Term Sheet (the "Term Sheet") with YOFOTO (China) Health Industry Co. Ltd. ("YOFOTO") to form a strategic partnership (the "Transaction") in Greater China (Mainland China, Hong Kong, Macau, and Taiwan) (the "Territory").

  • RepliCel Life Sciences Successfully Closes Financing
    CNW Group6 months ago

    RepliCel Life Sciences Successfully Closes Financing

    VANCOUVER, Oct. 19, 2017 /CNW/ - RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB:REPCD - News) (TSX.V:RP.V - News) (Frankfurt:P6P2.F - News), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announces that, further to its News Releases of October 10, 2017 and October 12, 2017, it has closed its non-brokered private placement of 2,815,881 common shares (each, a "Share") at a price of $0.41 per Share for gross proceeds of $1,154,511.21 (the "Offering"). "We are pleased to have secured the support of several key shareholders in the closing of a financing on terms which are favourable to the Company as we execute on the third and final major deliverable we had set out for the Company in 2017," stated RepliCel CEO Lee Buckler.